Skip to main content
. 2020 Sep 29;21:70. doi: 10.1186/s40360-020-00446-x

Fig. 1.

Fig. 1

MRD markers and donor chimerism in best responding patient. a/b MRD measurement via KMT2A/MLLT1 transcripts and IgH rearrangement in the best responding BPC-ALL patient revealed a response via SCT, but finally sustaining molecular response was reached via BEZ 235 treatment. c Donor chimerism in bone marrow was incomplete after allogeneic SCT with 1–5% autologous signal at day + 29 after SCT and dropping at early relapse. Soon after start of treatment with BEZ complete chimerism was reached